Published in J Neurooncol on February 10, 2010
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 1.41
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol (2011) 1.07
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 1.05
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer (2012) 0.91
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol (2014) 0.86
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology (2015) 0.85
Personalized medicine for gliomas. Surg Neurol Int (2015) 0.85
Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol (2012) 0.84
Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer (2014) 0.83
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res (2014) 0.83
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82
Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol (2012) 0.80
Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol (2015) 0.79
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr (2013) 0.78
Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med Chem (2010) 0.78
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol (2016) 0.78
DCVax®-L--developed by Northwest Biotherapeutics. Hum Vaccin Immunother (2014) 0.76
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75
Classifying Glioblastoma Multiforme Follow-Up Progressive vs. Responsive Forms Using Multi-Parametric MRI Features. Front Neurosci (2017) 0.75
Optimizing the process of nucleofection for professional antigen presenting cells. BMC Res Notes (2015) 0.75
Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. J Immunol Res (2016) 0.75
Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. Immunotargets Ther (2014) 0.75
Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy (2016) 0.75
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med (2015) 3.37
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet (2011) 2.74
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Preliminary clinical experience with the Bryan Cervical Disc Prosthesis. Neurosurgery (2002) 2.35
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer (2010) 2.35
Long-term follow-up after interbody fusion of the cervical spine. J Spinal Disord Tech (2004) 2.34
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
A confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor structure across clinical and non-clinical populations. Pain (2002) 2.18
The child version of the pain catastrophizing scale (PCS-C): a preliminary validation. Pain (2003) 2.10
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys (2002) 2.00
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
Lateral head impacts and protection of the temporal area by bicycle safety helmets. J Trauma (2007) 1.94
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2009) 1.92
International prevalence of adolescent non-suicidal self-injury and deliberate self-harm. Child Adolesc Psychiatry Ment Health (2012) 1.92
Intermediate follow-up after treatment of degenerative disc disease with the Bryan Cervical Disc Prosthesis: single-level and bi-level. Spine (Phila Pa 1976) (2003) 1.89
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol (2004) 1.65
Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer (2012) 1.60
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol (2002) 1.59
Catastrophic thinking about pain is independently associated with pain severity, disability, and somatic complaints in school children and children with chronic pain. J Pediatr Psychol (2005) 1.52
Clinical significance of heterotopic ossification in cervical disc replacement: a prospective multicenter clinical trial. Neurosurgery (2005) 1.49
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45
Gliomas: diffusion kurtosis MR imaging in grading. Radiology (2012) 1.45
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2002) 1.45
Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol (2007) 1.42
HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res (2007) 1.42
The Bryan Cervical Disc: wear properties and early clinical results. Spine J (2004) 1.41
Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest (2005) 1.41
Unilateral white matter involvement in Krabbe disease. Arch Neurol (2011) 1.38
Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease. Mov Disord (2013) 1.38
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36
Longitudinal prospective long-term radiographic follow-up after treatment of single-level cervical disk disease with the Bryan Cervical Disc. Neurosurgery (2010) 1.34
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiol Aging (2008) 1.31
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging (2004) 1.30
A clinical analysis of 4- and 6-year follow-up results after cervical disc replacement surgery using the Bryan Cervical Disc Prosthesis. J Neurosurg Spine (2010) 1.30
Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer (2013) 1.29
Assessing the affective features of psychopathy in adolescence: a further validation of the inventory of callous and unemotional traits. Assessment (2009) 1.27
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol (2004) 1.26
Confirmatory factor analysis of the Tampa Scale for Kinesiophobia: invariant two-factor model across low back pain patients and fibromyalgia patients. Clin J Pain (2004) 1.25
Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol (2005) 1.25
Temperament and risk for depressive symptoms in adolescence: mediation by rumination and moderation by effortful control. J Abnorm Child Psychol (2009) 1.25
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother (2012) 1.24
Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer (2002) 1.24
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Extramammary myofibroblastoma is genetically related to spindle cell lipoma. Virchows Arch (2006) 1.21
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol (2008) 1.20
Magnetic resonance imaging study of the level of termination of the conus medullaris and the thecal sac: influence of age and gender. Spine (Phila Pa 1976) (2005) 1.20
Gastrointestinal stromal tumor of the prostate. Urology (2005) 1.19
Gray's Reinforcement Sensitivity Theory as a framework for research on personality-psychopathology associations. Clin Psychol Rev (2009) 1.19
Primary peripheral PNET/Ewing's sarcoma of the dura: a clinicopathologic entity distinct from central PNET. Mod Pathol (2002) 1.19
Non-suicidal and suicidal self-injurious behavior among Flemish adolescents: A web-survey. Arch Suicide Res (2011) 1.17
Borderline personality symptoms differentiate non-suicidal and suicidal self-injury in ethnically diverse adolescent outpatients. J Child Psychol Psychiatry (2010) 1.16
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res (2008) 1.16
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer (2014) 1.16
Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol (2009) 1.15
Rocuronium exacerbates mechanical ventilation-induced diaphragm dysfunction in rats. Crit Care Med (2006) 1.15
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol (2013) 1.14
Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res (2011) 1.14
Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer (2002) 1.12
Pericardial synovial sarcoma: 14-year survival with multimodality therapy. Ann Thorac Surg (2004) 1.12
Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol (2004) 1.11
D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet (2003) 1.10
Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathol (2010) 1.10
Distinct histological features characterize primary angiosarcoma of bone. Histopathology (2011) 1.10
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 1.09
Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol (2004) 1.08
Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer (2012) 1.07
Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma. Virchows Arch (2004) 1.06
Dendritic cell therapy of high-grade gliomas. Brain Pathol (2009) 1.05